Mantle Cell Lymphoma | Specialty

The OncLive Mantle Cell Lymphoma condition center page is a comprehensive resource for clinical news and expert insights on mantle cell lymphoma treatment. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, therapeutic advances, and ongoing research in mantle cell lymphoma.

OncLive’s August EMA Regulatory Recap: Key EU Approvals in Oncology

September 3rd 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in August 2025.

Sonrotoclax Hits Primary End Point in Phase 1/2 Trial of Relapsed/Refractory MCL

August 29th 2025

A phase 1/2 trial met its primary end point of ORR with sonrotoclax in patients with relapsed/refractory MCL.

Five Under 5: Top Oncology Videos for the Week of 8/17

August 24th 2025

The top 5 OncLive videos of the week cover insights in polycythemia vera, multiple myeloma, colorectal cancer, LBCL, and mantle cell lymphoma.

Dr Dreyling on the Efficacy of Frontline Acalabrutinib Plus BR in High-Risk MCL

August 21st 2025

Martin Dreyling, MD, PhD, discusses the efficacy of first-line acalabrutinib plus BR in high-risk patients with mantle cell lymphoma.

Dr Jerkeman on the Importance of Recognizing the Biological Heterogeneity Within MCL

August 19th 2025

Mats Jerkeman, MD, discusses the importance of conducting further research to classify the biological heterogeneity within MCL.

Five Under 5: Top Oncology Videos for the Week of 8/10

August 17th 2025

The top 5 OncLive videos of the week cover insights in MCL, prostate cancer, plexiform neurofibromas, breast cancer, and follicular lymphoma.

Declining MCL Incidence Aligns With Broader Lymphoma Trends, But Survival Disparities Persist

August 14th 2025

Ruby Arora, MD, discusses an analysis of SEER data on the declining MCL incidence and disparities that persist in Hispanic and American Indian patients.

Dr Jerkeman on Induction Chemoimmunotherapy Followed by High-dose Chemo and ASCT in Younger Patients With MCL

August 13th 2025

Mats Jerkeman, MD, discusses the use of induction chemoimmunotherapy followed by high-dose chemotherapy and ASCT in younger patients with MCL.

LV20.19 CAR T-Cell Therapy Yields 100% ORR in R/R Mantle Cell Lymphoma

August 11th 2025

LV20.19 CAR T therapy produced an 88% CR rate and 100% ORR in relapsed/refractory mantle cell lymphoma.

Acalabrutinib Plus BR Highlights Evolving First-Line SOC for High-Risk Mantle Cell Lymphoma

August 8th 2025

Martin Dreyling, MD, PhD, discusses clinical trial findings with acalabrutinib plus BR in patients with high-risk mantle cell lymphoma.

FDA Grants RMAT Designation to Novel CAR T-Cell Therapy for R/R Mantle Cell Lymphoma

August 8th 2025

The FDA granted regenerative medicine advanced therapy designation to GLPG5101 for relapsed/refractory mantle cell lymphoma.

FDA Approves Tocilizumab Biosimilar for CAR T-Cell Therapy–Induced CRS

August 6th 2025

The FDA has expanded the indication for tocilizumab IV infusion to include the treatment of adult and pediatric patients with CRS.

OncLive’s July EMA Regulatory Recap: Key EU Approvals in Oncology

August 6th 2025

Here is your snapshot of all oncologic therapeutic options that were approved by the EMA in July 2025.

Five Under 5: Top Oncology Videos for the Week of 7/27

August 3rd 2025

The top 5 OncLive videos of the week cover insights in lung cancer, myelofibrosis, and mantle cell lymphoma.

Dr Kamdar on Optimizing Patient Monitoring After Liso-Cel in MCL

July 29th 2025

Manali Kamdar, MD, discusses the rationale for optimizing monitoring after the treatment of liso-cel in patients with mantle cell lymphoma.

Sonrotoclax Plus Zanubrutinib Generates Durable Responses in R/R Mantle Cell Lymphoma

July 25th 2025

The combination of sonrotoclax and zanubrutinib produced deep and durable responses in relapsed/refractory mantle cell lymphoma.

FDA Approves Generic Ibrutinib Tablets for B-Cell Malignancies

July 24th 2025

The FDA has approved a generic version of ibrutinib tablets for B-cell malignancies.

European Commission Approves Ibrutinib in Treatment-Naive, Transplant-Eligible MCL

July 23rd 2025

Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.

Long-Term Data Suggest Potential Functional Cure With MCL2/MCL3 Regimen in Younger Patients With Mantle Cell Lymphoma

July 20th 2025

Mats Jerkeman, MD, discusses long-term follow-up data of the Nordic MCL2 and MCL3 trials in younger patients with mantle cell lymphoma.

Dr Kamdar on Patient Monitoring After Liso-Cel in MCL and Hematologic Malignancies

July 14th 2025

Manali Kamdar, MD, discusses an analysis of the timing of CRS and ICANS among patients with MCL and other hematologic malignancies treated with liso-cel.